{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhan W"],"funding":["NCI NIH HHS"],"pagination":["1565-8"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3249659"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(8)"],"pubmed_abstract":["A conformationally restrained epothilone A analogue (3) with a short bridge between methyl groups at C6 and C8 was designed and synthesized. Preliminary biological evaluation indicates 3 to be only weakly active (IC50 = 8.5 microM) against the A2780 human ovarian cancer cell line."],"journal":["Organic letters"],"pubmed_title":["Design and synthesis of C6-C8 bridged epothilone A."],"pmcid":["PMC3249659"],"funding_grant_id":["R01 CA069571","R01 CA069571-13","CA 69571","R01 CA069571-12"],"pubmed_authors":["Jiang Y","Brodie PJ","Kingston DG","Liotta DC","Snyder JP","Zhan W"],"additional_accession":[]},"is_claimable":false,"name":"Design and synthesis of C6-C8 bridged epothilone A.","description":"A conformationally restrained epothilone A analogue (3) with a short bridge between methyl groups at C6 and C8 was designed and synthesized. Preliminary biological evaluation indicates 3 to be only weakly active (IC50 = 8.5 microM) against the A2780 human ovarian cancer cell line.","dates":{"release":"2008-01-01T00:00:00Z","publication":"2008 Apr","modification":"2025-04-19T13:48:55.218Z","creation":"2019-03-27T00:47:33Z"},"accession":"S-EPMC3249659","cross_references":{"pubmed":["18355076"],"doi":["10.1021/ol800422q"]}}